Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more
Vivoryon Therapeutics N.V. (0R3M) - Total Liabilities
Latest total liabilities as of June 2025: €3.24 Million EUR
Based on the latest financial reports, Vivoryon Therapeutics N.V. (0R3M) has total liabilities worth €3.24 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vivoryon Therapeutics N.V. - Total Liabilities Trend (2010–2024)
This chart illustrates how Vivoryon Therapeutics N.V.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vivoryon Therapeutics N.V. Competitors by Total Liabilities
The table below lists competitors of Vivoryon Therapeutics N.V. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
088340
KQ:088340
|
Korea | ₩18.07 Billion |
|
Ultimate Holdings Group Inc.
OTCGREY:UHGI
|
USA | $539.67K |
|
JHM Consolidation Bhd
KLSE:0127
|
Malaysia | RM189.32 Million |
|
MBT Bancshares Inc
PINK:MBKL
|
USA | $352.55 Million |
|
TeraGo Inc
PINK:TRAGF
|
USA | $54.62 Million |
|
iMBC Co.Ltd
KQ:052220
|
Korea | ₩11.04 Billion |
|
iCRAFT Co. Ltd
KQ:052460
|
Korea | ₩65.51 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Vivoryon Therapeutics N.V.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vivoryon Therapeutics N.V.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vivoryon Therapeutics N.V. (2010–2024)
The table below shows the annual total liabilities of Vivoryon Therapeutics N.V. from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.40 Million | -25.14% |
| 2023-12-31 | €4.55 Million | -6.67% |
| 2022-12-31 | €4.87 Million | -38.82% |
| 2021-12-31 | €7.96 Million | +125.58% |
| 2020-12-31 | €3.53 Million | +10.45% |
| 2019-12-31 | €3.20 Million | +113313.77% |
| 2018-12-31 | €2.82K | +53.24% |
| 2017-12-31 | €1.84K | -69.30% |
| 2016-12-31 | €5.99K | +4.48% |
| 2015-12-31 | €5.73K | +4.07% |
| 2014-12-31 | €5.51K | -99.95% |
| 2013-12-31 | €10.60 Million | +128.41% |
| 2012-12-31 | €4.64 Million | +11.86% |
| 2011-12-31 | €4.15 Million | +11.30% |
| 2010-12-31 | €3.73 Million | -- |